top of page
Vaccine.png

RSV Vaccines

Respiratory Syncytial Virus (RSV) is a common virus that affects the respiratory system, particularly in infants, young children and older people. While most people experience mild symptoms, RSV can cause serious illnesses like bronchiolitis and pneumonia.​

WHAT IS RSV?

RSV is a highly contagious respiratory virus that affects the respiratory system. It is especially dangerous for:

  • Infants under six months, who are at risk of severe infections like bronchiolitis and pneumonia.

  • Premature babies, due to their underdeveloped lungs and weaker immune systems.

  • Elderly individuals, particularly those with underlying conditions such as asthma, COPD, or heart disease.

 

RSV spreads through respiratory droplets, close contact, or contaminated surfaces. Symptoms range from mild (runny nose, cough, low-grade fever) to severe (wheezing, difficulty breathing, or bluish lips). Severe cases can lead to complications such as bronchiolitis or pneumonia, often requiring hospitalisation.

RSV is most active in late autumn, winter, and early spring in Australia.

Symptoms of RSV include:

  • Runny nose

  • Cough and/or wheeze

  • Fever

  • Difficulty breathing in severe cases​

 

RSV VACCINE FOR OLDER PEOPLE AND ABORIGINAL OR TORRES STRAIT ISLANDER PEOPLE (Arexvy)

Arexvy will be offered to people aged 75 years and older and Aboriginal and Torres Strait Islander people aged 60 years and over, free of charge, from 15 May 2026.

Who is eligible for the government funded program?

  • People aged 75 years and over

  • Aboriginal and Torres Strait Islander people aged 60 years and over

Key information

  • A single dose of Arexvy is recommended.

  • The vaccine can be co-administered with other vaccines such as COVID-19, influenza, zoster and pneumococcal vaccines.

​​

How to access this vaccine

Online booking will be available from 15 May 2026. If you would like to secure a vaccine and book ahead, please phone our reception team on 02 9365 2833.

​​​​​​​​​

MATERNAL RSV VACCINE (Abrysvo®)

Abrysvo® is offered to pregnant women to protect their infants from RSV from birth up to 6 months of age.

Who is eligible for the government funded program?​​

Pregnant women between 28 and 36 weeks gestation.

Key information

  • A single dose of Abrysvo® is recommended during this time frame.

  • The vaccine can be co-administered with Pertussis and Influenza vaccines.

​​​

How to access this vaccine

You can book directly with our nurse to receive the vaccine.​​

​​

NIRSEVIMAB (Beyfortus™) FOR INFANTS

Nirsevimab, a monoclonal antibody, is available to protect eligible infants from severe RSV disease.

Who is eligible for the government funded program?
Infants up to 24 months of age who are not protected through maternal vaccination OR have risk factors for severe RSV disease.


How to access this vaccine

All infants who may be eligible must first have an appointment with a GP to assess their eligibility. If eligible, the vaccine will be ordered specifically for your child, as we are unable to stock it in bulk.

Related Services

bottom of page